Haemonetics HAE Plasma — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's plasma — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's plasma — operating income?
- Haemonetics (HAE) reported plasma — operating income of $43.69M in Q1 2026.
- How has Haemonetics's plasma — operating income changed year-over-year?
- Haemonetics's plasma — operating income decreased by 13.7% year-over-year, from $50.63M to $43.69M.
- What is the long-term trend for Haemonetics's plasma — operating income?
- Over 2 years (2022 to 2026), Haemonetics's plasma — operating income has grown at a 0.5% compound annual growth rate (CAGR), from $183.13M to $184.8M.
- What does plasma — operating income mean?
- Measures the profitability of the plasma segment by subtracting operating expenses, such as cost of goods sold and research and development, from total segment revenues. It serves as a primary indicator of the operational efficiency and core earnings power of the plasma business unit. A stable or growing operating income suggests effective cost management and strong market demand for plasma collection products.